Manager Development

Zhaohui (Vincent) Wang, Ph.D.

**** ********** *****, *********, ***** 76051

Cell: 682-***-****; Email: ************@*******.***

* Permanent resident of the United States

CERTIFICATION

Technologist in Molecular Biology (ASCP)

SUMMARY OF QUALIFICATIONS

Molecular assay development in support of regulatory filings to FDA

●Designed, validated and performed modified 5’ RACE-PCR assays to examine

molecular mechanism of RNA interference for animal and clinical studies (GLP

settings; products have been approved by FDA and are currently in Phase I and II)

●Developed RT-QPCR based assay to determine mRNA genotype of Ewing’s sarcoma

and quantify mRNA expression

●Developed allele-specific RT-QPCR to determine mRNA genotype of Kras

●Developed RT-QPCR to determine biomarkers in pancreatic cancer

●Designed, validated and performed RT-QPCR based microRNA assays for

biodistribution study of cancer therapeutics in animal studies and clinical studies (GLP

settings)

● Prepared documentation for IND submissions to FDA

Preclinical and clinical studies on RNA Interference and autologous vaccine

(cancer therapeutics)

●Conducted preclinical and clinical studies for regulatory filings of RNA interference

therapeutics

●Performed preclinical studies including design of RNAi drug, screening of lead RNAi,

identification of RNAi mechanism, and study of biodistribution of RNAi molecules in

vivo

●Conducted preclinical studies for regulatory filings of an autologous cancer vaccine

●Led several RNAi discovery projects aiming at silencing oncogenic genes in

melanoma, pancreatic cancer and breast cancer

Project management

●Managed and coordinated external collaborations with multiple CROs and academic

institutions

●Supervised and trained personnel (summer interns and technical staff)

●Prepared manuscripts, grants applications, SOPs, study protocols and scientific

research articles

●Presented and discussed product development in meetings and conferences

Bioinformatics

●Identified potential targets and signal pathways for cancer therapeutics by analyzing

microarray data from clinical tumor specimens

●Identified potential microRNA targets for cancer therapeutics by mining microRNA

database

●Extensive experience in GeneSpring / dChip / GSEA and other bioinformatics tools

Techniques

●Extensive experience in Real-time PCR, microarray, microRNA analysis, genotyping,

and cellular assays (fluorescence, luminescence, apoptosis, cell proliferation,

cytotoxicity and ELISA)

●Extensive experience in standard molecular biology techniques (molecular cloning,

southern/northern/western blotting, PCR and QPCR, nucleic acid extraction, and gel

electrophoresis)

●Extensive experience in establishment and application of in vitro assay (MTS assay,

LDH assay, reporter assay, flow cytometry and so on)

●Extensive experience in flow cytometer, fluorescent microscope, fluorescent

quantitative assay and immunological assay

PROFESSIONAL EXPERIENCE

2007- Present Research Associate

Gradalis Inc. (Dallas, Texas)

●Developed molecular assays to support biopharmaceutical

development from preclinical to clinical stage

●Led several RNAi discovery projects aiming at silencing oncogenic

genes in melanoma, pancreatic cancer and breast cancer

●Performed preclinical and clinical studies on RNAi-based drugs and

vaccine in support of regulatory filings for cancer therapeutics

2001-2007 Research Assistant

University of North Texas Health Science Center (Fort Worth, Texas)

●Investigated the potential roles of MAPKs in pathogenesis of age-

related macular degeneration

●Investigated the candidacy of stem-cell therapy in age-related

macular degeneration

●Developed a cataract transgenic animal model with overexpression

of the Na/Myo-Inositol Co-Transporter

2000-2001 Product Manager

Simcere Pharmaceutical Group (Nanjing, China)

●Coordinated the development of marketing strategies, advertising

and promotion programs of an osteoporosis drug and ensured their

implementation.

●Developed and conducted specialized training on new products

launched and provided technical support

1999-2000 Clinical Representative

GlaxoSmithKline Pharmaceuticals (China Division)

● Educated customers on the merits and clinical usage of company

products by giving presentations and demonstrations

● Performed clinical and library research and participated in case

reviews and clinical observation

1993-1996 Research Scientist

North China Pharmaceutical Group Corp. (China)

● Product development of anticancer recombinant proteins

EDUCATION

2001-2007 Ph.D., Biomedical Science

University of North Texas Health Science Center (Fort Worth, Texas)

● Dissertation: Molecular mechanisms of and potential therapies for

oxidative damage to the retinal pigment epithelium

1996-1999 M.S., Biopharmaceutics

China Pharmaceutical University (Nanjing, China)

1989-1993 B.S., Pharmacy

China Pharmaceutical University (Nanjing, China)

SELECTIVE HONORS AND AFFILLIATIONS

● Member of American Society of Gene & Cell Therapy (2008-present)

● Member of Sigma Xi Scientific Research Society

● Member of Association for Research in Vision and Ophthalmology (2001-2007)

● Outstanding Graduate Student Award, 1997, China Pharmaceutical University

● Merit-Based Fellowship, 1993 China Pharmaceutical University

PATENTS

1. Methods and compositions to treat cancer using bi-functional SRC3 shRNA. United

States Patent Application 201******** (2013)

2. Chemosensitization by bi-functional small hairpin RNA (bi-shRNA). United States

Patent Application 201******** (2011)

SELECTED PUBLICATIONS

1. Wang Z, Rao D, Senzer N, Nemunaitis J. Preclinical biodistribution and safety

evaluation of pbi-shSTMN1 lipoplex after subcutaneous injection in rats.(In

preparation)

2. Wang Z, Bartosh TJ, Ding M, Roque RS. (2013) MAPKs modulate Retinal

Pigment Epithelium (RPE) response to oxidative stress. J. Medical and

Bioengineering. 3(1):67-73.

3. Rao DD, Wang Z, Senzer N, Nemunaitis J. (2013) RNA interference and

personalized cancer therapy. Discov Med. 15(81):101-10.

4. Rao DD, Senzer N, Wang Z, Kumar P, Jay CM, Nemunaitis J. (2013) Bi-functional

Short Hairpin RNA (bi-shRNA): Design and Pathway to Clinical Application.

Methods in Molecular Biology. 942:259-78.

5. Liu SH, Rao DD, Nemunaitis J, Senzer N, Zhou G, Dawson D, Gingras MC, Wang

Z, Gibbs R, Norman M, Templeton NS, Demayo FJ, O'Malley B, Sanchez R,

Fisher WE, Brunicardi FC.(2012) PDX-1 is a therapeutic target for pancreatic

cancer, insulinoma and islet neoplasia using a novel RNA interference platform.

PLoS One. 7(8).

6. Senzer N, Barve M, Kuhn J, Melnyk A, Beitsch P, Lazar M, Lifshitz S, Magee M,

Oh J, Mill SW, Bedell C, Higgs C, Kumar P, Yu Y, Norvell F, Phalon C, Taquet N,

Rao DD, Wang Z, Jay CM, Pappen BO, Wallraven G, Brunicardi FC, Shanahan

DM, Maples PB, Nemunaitis J. (2012) Phase I Trial of “bi-shRNAifurin/GMCSF

DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer. Mol Ther.

20(3):679-86.

7. Wang Z, Rao D, Senzer N, Nemunaitis J. (2011) RNA Interference and Cancer

Therapy. Pharmaceutical Research, 28(12), 2983-2995. (Invited Review)

8. Phadke AP, Jay CM, Wang Z, Chen S, Liu S, et al. (2011) In vivo safety and

antitumor efficacy of bifunctional small hairpin RNAs specific for the human

Stathmin 1 oncoprotein. DNA Cell Biol. 30(9):715-26.

9. Rao D, Maples PB, Senzer N, Kumar P, Wang Z, et al. (2010) Enhanced Target

Gene Knockdown by a Bifunctional shRNA: A Novel Approach of RNA

Interference. Cancer Gene Ther. 17(11):780-91.

10. Maples PB, Kumar P, Yu Y, Wang Z, Jay CM, et al. (2009) Fang Vaccine:

Autologous Tumor Cell Vaccine Genetically Modified to Express GM-CSF and

Block Production of Furin. BioProcess. J. 8(4): 4-14.

11. Phadke AP, Jay C, Chen SJ, Haddock C, Wang Z, Yu Y, et al. (2009) Safety and

in vivo Expression of a GNE-Transgene: A Novel Treatment Approach for

Hereditary Inclusion Body Myopathy-2. Gene Regul Syst Bio. (3) 89–101.

12. Bartosh TJ, Wang Z, Rosales AA, Dimitrijevich SD, Roque RS. (2008) 3D-model

of adult cardiac stem cells promotes differentiation and resistance to oxidative

stress. J. Cellular Biochemistry. 105(2):612-23.

13. Srinivasan B, Wang Z, Brun-Zinkernagel AM, Collier RJ, Chao M, Black, RA,

Frank SJ, Barker PA, Roque RS. (2007) Photic injury promotes cleavage of

p75NTR by TACE and nuclear trafficking of the p75 intracellular domain. Mol.

Cell. Neurosci. 36(4):449-61

14. Sheedlo HJ, Bartosh TJ, Wang Z, Srinivasan B, Brun-Zinkernagel AM, Roque RS.

(2007) RPE-derived factors modulate photoreceptor differentiation: a possible role

in the retinal stem cell niche. In Vitro Cell Dev Biol Anim. 43(10):361-70.

15. Cammarata PR, Chu S, Moor A, Wang Z. (2004) Subcellular distribution of native

estrogen receptor α and β subtypes in cultured human lens epithelial cells. Exp.

Eye Res. 78: 867-871.

16. Wang Z, Ding M, Liu J. (1999) Synthesis, cloning and fusion Expression of the

hPTH N-terminus 34 Peptide Gene. Journal of China Pharmaceutical

University 30(3): 216-9.

Contact this candidate